Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target
Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is bullish on the company’s integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29. Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key…
Jefferies has begun providing coverage for Anthem Biosciences with a Buy rating and a target price of Rs 1,050. This implies a potential upside of around 20% from the company's current market price of Rs 874.15. The brokerage cites Anthem's differentiated capabilities across small- and large-molecule therapeutics, strong return ratios, and a promising growth runway as the reasons for their bullish stance.
Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
